文献速递神经MR

钆特酸葡甲胺与钆布醇在原发性脑肿瘤MRI诊断中的比较:双盲随机对照个体内交叉研究(REMIND研究)

Comparison of Gadoterate Meglumine and Gadobutrol in the MRI Diagnosis of Primary Brain Tumors: A Double-Blind Randomized Controlled Intraindividual Crossover Study (the REMIND Study).
PubMed 文献 · AJNR Am J Neuroradiol · 2017-06-29

这项多中心、双盲、随机、对照、个体内交叉、非劣效性研究纳入279例患者,比较钆特酸葡甲胺与钆布醇(剂量均为0.1 mmol/kg体重)对原发性脑肿瘤整体显示与表征的效果。两种对比剂在多数患者(>90%)中均获良好或优秀评分,钆特酸葡甲胺对钆布醇的非劣效性得到统计学证明;钆布醇的定量平均病灶强化百分比更高(P < .001),但定性终点无显著差异;不良事件发生率相近(钆特酸葡甲胺7.8% vs 钆布醇7.3%)。

要点

  • 钆特酸葡甲胺与钆布醇在原发性脑肿瘤整体显示与表征上非劣效,多数患者评分良好或优秀。
  • 钆布醇的定量平均病灶强化百分比高于钆特酸葡甲胺(P < .001),但定性评估无显著差异。
  • 两种对比剂不良事件发生率相近(7.8% vs 7.3%),主要为注射部位疼痛。

核心结论

  • 钆特酸葡甲胺对钆布醇在原发性脑肿瘤整体显示与表征方面非劣效性得到证明。

研究设计与样本

  • 多中心、双盲、随机、对照、个体内交叉、非劣效性研究,纳入279例患者,两种对比剂剂量均为0.1 mmol/kg体重,间隔2-14天进行2次相同MRI检查,主要终点由3名离线读者独立按4分法(差到优秀)评分。

诊断标准与关键数值

  • 主要终点为整体病灶显示与表征,由3名离线读者独立按4分法评分(差、一般、良好、优秀)。
  • 3名读者对两种对比剂均将多数患者(>90%)的图像评为良好或优秀。
  • 钆特酸葡甲胺对钆布醇的非劣效性得到统计学证明。
  • 定量平均病灶强化百分比钆布醇更高(P < .001)。
  • 诊断信心高/优秀者在两种对比剂中均>81%。

临床应用与阅片要点

  • 作者结论为钆特酸葡甲胺对钆布醇在原发性脑肿瘤整体显示与表征上非劣效。
  • 定性评估(病灶边界勾画、内部形态、对比强化程度、诊断信心)两种对比剂无显著差异。
  • 不良事件发生率钆特酸葡甲胺7.8% vs 钆布醇7.3%,主要为注射部位疼痛。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: Effective management of patients with brain tumors depends on accurate detection and characterization of lesions. This study aimed to demonstrate the noninferiority of gadoterate meglumine versus gadobutrol for overall visualization and characterization of primary brain tumors.

MATERIALS AND METHODS: This multicenter, double-blind, randomized, controlled intraindividual, crossover, noninferiority study included 279 patients. Both contrast agents (dose = 0.1 mmol/kg of body weight) were assessed with 2 identical MRIs at a time interval of 2-14 days. The primary end point was overall lesion visualization and characterization, scored independently by 3 off-site readers on a 4-point scale, ranging from "poor" to "excellent." Secondary end points were qualitative assessments (lesion border delineation, internal morphology, degree of contrast enhancement, diagnostic confidence), quantitative measurements (signal intensity), and safety (adverse events). All qualitative assessments were also performed on-site.

RESULTS: For all 3 readers, images of most patients (>90%) were scored good or excellent for overall lesion visualization and characterization with either contrast agent; and the noninferiority of gadoterate meglumine versus gadobutrol was statistically demonstrated. No significant differences were observed between the 2 contrast agents regarding qualitative end points despite quantitative mean lesion percentage enhancement being higher with gadobutrol (P < .001). Diagnostic confidence was high/excellent for all readers in >81% of the patients with both contrast agents. Similar percentages of patients with adverse events related to the contrast agents were observed with gadoterate meglumine (7.8%) and gadobutrol (7.3%), mainly injection site pain.

CONCLUSIONS: The noninferiority of gadoterate meglumine versus gadobutrol for overall visualization and characterization of primary brain tumors was demonstrated.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Maravilla KR, San-Juan D, Kim SJ, et al. Comparison of Gadoterate Meglumine and Gadobutrol in the MRI Diagnosis of Primary Brain Tumors: A Double-Blind Randomized Controlled Intraindividual Crossover Study (the REMIND Study). AJNR Am J Neuroradiol. 2017. PMID: 28663267. doi:10.3174/ajnr.A5316

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。